Analysis of Medicine Prices in New Zealand and 16 European Countries
- 1 June 2015
- journal article
- research article
- Published by Elsevier BV in Value in Health
- Vol. 18 (4), 484-492
- https://doi.org/10.1016/j.jval.2015.01.003
Abstract
No abstract availableKeywords
This publication has 21 references indexed in Scilit:
- Higher US Branded Drug Prices And Spending Compared To Other Countries May Stem Partly From Quick Uptake Of New DrugsHealth Affairs, 2013
- Differences in external price referencing in Europe—A descriptive overviewHealth Policy, 2012
- The effects of drug market regulation on pharmaceutical prices in Europe: overview and evidence from the market of ACE inhibitorsHealth Economics Review, 2011
- Determinants of branded prescription medicine prices in OECD countriesHealth Economics, Policy and Law, 2011
- Comparing pharmaceutical pricing and reimbursement policies in Croatia to the European Union Member StatesCroatian Medical Journal, 2011
- Medicine prices, availability, and affordability in 36 developing and middle-income countries: a secondary analysisThe Lancet, 2009
- European prices of newly launched reimbursable pharmaceuticals – a pilot studyHealth Policy, 2005
- The concept of essential medicines: lessons for rich countriesBMJ, 2004
- Prices And Availability Of Pharmaceuticals: Evidence From Nine CountriesHealth Affairs, 2003
- Cross-national price differences for pharmaceuticals: how large, and why?Journal of Health Economics, 2000